Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Biosimilars Advisory Service : Acceptance of Biosimilars Across Physician Specialties | US,France and Germany | 2015
Gaining physician confidence is critical to securing a meaningful position in developed markets; therefore, understanding their concerns about biosimilar products should be an important part of…
Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology (Physician Perspectives) | Biosimilars Advisory Service | US/Eu5/Japan | 2014
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties | Biosimilars Advisory Service | US/EU | 2014
The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…
Contemporary Topics in the Treatment of Non-Small-Cell Lung Cancer: Physicians, Payers, and Pathologists as Gatekeepers to Market Access
Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…